PRESS RELEASEGetinge 2013-01-11
Getinge announces preliminary results for 2012
Demand for the Getinge Group’s products weakened during the final quarter of 2012, which had an adverse impact on orders received and invoicing volume. For the full-year, orders received and invoicing rose organically by nearly 3%, which was lower than the expected volume growth. The demand for capital goods was particularly weak in Western Europe and Eastern Europe.
Due to lower invoicing volumes during the final quarter of the year, consolidated net profit before tax fell short of expectations, totaling approximately SEK 3,600 million for the full-year, excluding acquisition and restructuring costs related to TSS. As previously announced, acquisition and restructuring costs of SEK 170 million associated with the purchase of TSS will be charged to Getinge’s profit for 2012.
This announcement will be followed by a conference call at 2:00 PM (CET), hosted by Johan Malmquist, CEO, Getinge Group, and Ulf Grunander, CFO, Getinge Group.
Getinge will issue its year-end report for 2012 on January 25.
To participate, please call:
In Sweden: +46 8 5352 6408
In the UK: +44 20 7136 2051
In the US: +1 212 444 0481
Participant code: 6776524
1:45 pm – Call the conference number
2:00 pm – Introduction
2:10 pm – Q&A
3:00 pm – End of conference
A recorded version of the conference will be accessible for five working days at the following number:
Sweden: +46 8 5051 3897
UK: +44 20 3427 0598
US: +1 347 366 9565
For further information, please contact:
Johan Malmquist Ulf Grunander
CEO, Getinge Group CFO, Getinge Group
GETINGE GROUP is a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within healthcare and life sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and MAQUET. ArjoHuntleigh focuses on patient mobility and wound management solutions. GETINGE provides solutions for infection control within healthcare and contamination prevention within life sciences. MAQUET specializes in solutions, therapies and products for surgical interventions, interventional cardiology and intensive care.
The information is such that Getinge AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.